SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
Yuqin Song, Yanyan Liu, Zhiming Li, Lanfang Li, Hang Su, Zhengming Jin, Xuelan Zuo, Jianyuan Wu, Hui Zhou, Kunyan Li, Chuan He, Jianfeng Zhou, Junyuan Qi, Siguo Hao, Zhen Cai, Yijing Li, Weiwei Wang, Xiaojing Zhang, Jianjun Zou, Jun Zhu
Topics & Concepts
MedicineInternal medicineClinical endpointRefractory (planetary science)LymphomaAdverse effectPharmacodynamicsClinical trialPhases of clinical researchGastroenterologyOncologyPharmacokineticsSurgeryAstrobiologyPhysicsLymphoma Diagnosis and TreatmentEpigenetics and DNA MethylationAcute Lymphoblastic Leukemia research